Perspective Therapeutics, Inc.
CATX
$3.46
-$0.22-5.98%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.24M | 1.47M | 1.45M | 1.56M | 1.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24M | 1.47M | 1.45M | 1.56M | 1.46M |
| Cost of Revenue | 68.53M | 61.88M | 55.63M | 36.55M | 36.55M |
| Gross Profit | -67.06M | -60.18M | -53.95M | -34.99M | -35.08M |
| SG&A Expenses | 30.77M | 28.58M | 26.61M | 23.31M | 20.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 15.00K | 15.00K |
| Total Operating Expenses | 86.64M | 77.10M | 68.25M | 59.16M | 50.18M |
| Operating Income | -85.40M | -75.62M | -66.80M | -57.60M | -48.72M |
| Income Before Tax | -97.51M | -86.72M | -80.37M | -49.80M | -44.25M |
| Income Tax Expenses | -2.10M | -2.10M | -2.10M | 7.85M | 7.85M |
| Earnings from Continuing Operations | -95.41 | -84.62 | -78.27 | -57.65 | -52.10 |
| Earnings from Discontinued Operations | 455.00K | -549.00K | -1.01M | -6.13M | -6.92M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.95M | -85.17M | -79.28M | -63.79M | -59.02M |
| EBIT | -85.40M | -75.62M | -66.80M | -57.60M | -48.72M |
| EBITDA | -102.75M | -93.14M | -84.68M | -55.76M | -47.27M |
| EPS Basic | -1.32 | -1.21 | -1.21 | -1.52 | -1.67 |
| Normalized Basic EPS | -0.64 | -0.56 | -0.55 | -0.65 | -0.73 |
| EPS Diluted | -1.89 | -1.78 | -1.78 | -1.52 | -1.67 |
| Normalized Diluted EPS | -0.64 | -0.56 | -0.55 | -0.65 | -0.73 |
| Average Basic Shares Outstanding | 288.04M | 280.46M | 257.61M | 214.87M | 172.30M |
| Average Diluted Shares Outstanding | 288.04M | 280.46M | 257.61M | 214.87M | 172.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |